Mosley Wealth Management Makes New $111,000 Investment in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Mosley Wealth Management bought a new stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 14,746 shares of the company’s stock, valued at approximately $111,000.

A number of other large investors also recently made changes to their positions in the company. Los Angeles Capital Management LLC bought a new stake in Recursion Pharmaceuticals during the second quarter worth $246,000. Arizona State Retirement System grew its position in Recursion Pharmaceuticals by 11.1% during the second quarter. Arizona State Retirement System now owns 47,691 shares of the company’s stock valued at $358,000 after buying an additional 4,760 shares during the period. Victory Capital Management Inc. increased its holdings in Recursion Pharmaceuticals by 13.5% during the second quarter. Victory Capital Management Inc. now owns 21,891 shares of the company’s stock worth $164,000 after buying an additional 2,598 shares during the last quarter. Commons Capital LLC purchased a new position in Recursion Pharmaceuticals in the second quarter valued at about $833,000. Finally, Foundations Investment Advisors LLC boosted its stake in Recursion Pharmaceuticals by 296.1% in the second quarter. Foundations Investment Advisors LLC now owns 154,394 shares of the company’s stock valued at $1,158,000 after acquiring an additional 115,418 shares during the last quarter. 89.06% of the stock is owned by institutional investors.

Recursion Pharmaceuticals Stock Performance

Shares of Recursion Pharmaceuticals stock traded down $0.25 during trading hours on Friday, reaching $5.92. The company had a trading volume of 4,577,882 shares, compared to its average volume of 5,964,571. The firm has a market cap of $1.41 billion, a PE ratio of -3.70 and a beta of 0.82. Recursion Pharmaceuticals, Inc. has a one year low of $4.97 and a one year high of $15.74. The company has a debt-to-equity ratio of 0.04, a current ratio of 6.07 and a quick ratio of 6.07. The business has a fifty day simple moving average of $7.33 and a 200 day simple moving average of $8.85.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its earnings results on Thursday, August 8th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.05). Recursion Pharmaceuticals had a negative return on equity of 79.47% and a negative net margin of 755.37%. The company had revenue of $14.42 million during the quarter, compared to the consensus estimate of $11.96 million. During the same quarter in the prior year, the business earned ($0.38) EPS. The firm’s revenue for the quarter was up 30.9% compared to the same quarter last year. On average, analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.6 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the stock. Leerink Partners lowered their price target on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating on the stock in a report on Tuesday. KeyCorp lowered their target price on Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating on the stock in a research note on Thursday, July 11th. Jefferies Financial Group dropped their price target on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a research report on Tuesday. Finally, Needham & Company LLC decreased their price objective on Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating for the company in a report on Wednesday. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Recursion Pharmaceuticals presently has an average rating of “Hold” and an average target price of $9.40.

Insider Activity at Recursion Pharmaceuticals

In other news, CEO Christopher Gibson sold 50,000 shares of the business’s stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $7.48, for a total transaction of $374,000.00. Following the completion of the transaction, the chief executive officer now directly owns 758,738 shares in the company, valued at approximately $5,675,360.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CEO Christopher Gibson sold 50,000 shares of Recursion Pharmaceuticals stock in a transaction dated Wednesday, July 10th. The stock was sold at an average price of $7.48, for a total transaction of $374,000.00. Following the completion of the sale, the chief executive officer now owns 758,738 shares in the company, valued at approximately $5,675,360.24. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Blake Borgeson sold 11,447 shares of the company’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $6.27, for a total transaction of $71,772.69. Following the completion of the transaction, the director now owns 7,121,322 shares in the company, valued at $44,650,688.94. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 243,129 shares of company stock valued at $1,807,845. Corporate insiders own 15.75% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.